TIDMDEMG
RNS Number : 7894W
Deltex Medical Group PLC
28 April 2021
28 April, 2021
Deltex Medical Group plc
("Deltex Medical" or the "Group")
Grant of options
Deltex Medical Group plc (AIM: DEMG), the global leader in
Oesophageal Doppler Monitoring ("ODM"), announces that yesterday,
27 April 2021, the Board approved the issue of 14.5 million share
options to 7 existing employees and to Andy Mears, Chief Executive
Officer, under the Company's 2003 Share Option Scheme (the "EMI
Share Scheme").
Employee Share Option Scheme
Incorporated into the EMI Share Scheme, the Board has approved
the issue of 5,000,000 share options to Andy Mears, Chief
Executive. The exercise price for these shares is 1.80 pence per
share option, the closing price on 27 April 2021. The share options
for the Chief Executive may ordinarily be exercised between April
2024 and April 2031 and are subject to performance conditions which
are based on achieving certain specified earnings targets.
On 22 July 2020 the Company announced that it had granted
4,000,000 share options to Andy Mears, Chief Executive Officer, and
1,000,000 to David Moorhouse, Group Finance Director. This should
have said that the options were awarded under the 2011 Executive
Share Scheme rather than the 2003 EMI Share Scheme.
Confirmation of Directors' interests in share options
Following the grant of EMI options above, the options held by
Directors are shown below:
Executive Director 2011 Executive Share Scheme 2003 EMI Share Scheme Total
Number Number Number
Andy Mears 6,387,500 15,000,000 21,387,500
David Moorhouse 1,000,000 - 1,000,000
Nigel Keen, Deltex Medical's Chairman, commented:
"The Company has navigated its way through the lockdown period
successfully. All the indiciations are present that elective
surgery will return to more normal levels in the second half of
2021. The Company is well placed to take advantage of this and the
Board wished to motivate key employees by awarding these share
options. "
For further information, please contact:
Deltex Medical Group plc 01243 774 837
Nigel Keen, Chairman investorinfo@Deltexmedical.com
Andy Mears, Chief Executive
David Moorhouse, Group Finance Director
Arden Partners plc 020 7614 5900
Paul Shackleton
Dan Gee-Summons
Joint Broker
Turner Pope Investments (TPI) Ltd 0203 657 0050
Andy Thacker info@turnerpope.com
Zoe Alexander
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name a. Andy Mears (Chief Executive)
b. David Moorhouse (Group Finance Director)
-------------------------- -------------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status See 1 a) above
-------------------------- -------------------------------------------------
b) Initial notification Initial notification
/Amendment
-------------------------- -------------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Deltex Medical Group plc
-------------------------- -------------------------------------------------
b) LEI 213800XN34P6LI8J6M39
-------------------------- -------------------------------------------------
4 Details of the transaction(s): section to be repeated for
(i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions have
been conducted
-----------------------------------------------------------------------------
a) Description of the Issue of share options
financial instrument,
type of instrument Identification code (ISIN) for Deltex
Identification code Medical Group plc ordinary shares: GB0059337583
-------------------------- -------------------------------------------------
b) Nature of the transaction Issue of options
-------------------------- -------------------------------------------------
c) Price(s) and volume(s) Issue of share options
a. 5,000,000
-------------------------- -------------------------------------------------
d) Aggregated information
- Aggregated volume 5,000,000
- Price Exercisable at 1.80 pence
-------------------------- -------------------------------------------------
e) Date of the transaction 27.4.21
-------------------------- -------------------------------------------------
f) Place of the transaction Outside a trading venue
-------------------------- -------------------------------------------------
Notes for Editors
Deltex Medical manufactures and markets haemodynamic monitoring
technologies which are primarily used in critical care and general
surgical procedures. Deltex Medical's proprietary oesophageal
Doppler monitoring ("ODM") (TrueVue Doppler) measures blood flow
velocity in the central circulation in real time. Minimally
invasive, easy to set-up and quick to focus, the technology
generates a low-frequency ultrasound signal which is highly
sensitive to changes in blood flow and measures such changes in
'real time'. Deltex Medical is the only company in the enhanced
haemodynamic space to have built a robust and credible evidence
base demonstrating both the clinical and economic benefits of its
core technology: TrueVue Doppler. This technology has been proven
in a wide range of clinical trials to reduce complications suffered
by patients after surgery and consequently can save hospitals
money.
Deltex Medical's TrueVue System on the CardioQ-ODM+ monitor
platform now provides clinicians with two further advanced
haemodynamic monitoring technologies. TrueVue Impedance is an
entirely non-invasive monitoring technology which transmits low
magnitude, high frequency electrical signals through the thorax and
measures the changes to this signal when the heart pumps blood.
TrueVue PressureWave uses the peripheral blood pressure signal
analysis to give doctors information on changes in the circulation
and is particularly suited to monitoring lower risk or
haemodynamically stable patients.
Group goal
Haemodynamic management is now becoming widely accepted as a
vital part of the anaesthesia protocols for surgical patients, as
well as treating ventilated intensive care patients, including
ventilated COVID-19 patients. Consequently, the Group's focus is on
maximising value from the opportunities presented, as enhanced
haemodynamic management is adopted into routine clinical practice
around the world. The Group aims to provide clinicians with a
single platform - a 'haemodynamic workstation' - which offers them
a range of technologies from simple to sophisticated to be deployed
according to the patient's clinical condition as well as the skill
and expertise of the user. Doing this will enable the Group to
partner with healthcare providers to support modern haemodynamic
management across the whole hospital.
The Group is currently in the implementation phase of achieving
this goal in a number of territories worldwide, operating directly
in the UK and the USA, and via agreements with approximately 40
distributors overseas.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
IOEFLFLASAIDFIL
(END) Dow Jones Newswires
April 28, 2021 02:00 ET (06:00 GMT)
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Deltex Medical (LSE:DEMG)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
